Last reviewed · How we verify
Ménière's disease — Treatment Landscape & Competitive Intelligence
1 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Merislon | Merislon | Zhan Yunfan | Histamine H3 receptor, Histamine H3 receptor |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- · 2 drugs in Ménière's disease
- Zhan Yunfan · 1 drug in Ménière's disease
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Ménière's disease:
- Ménière's disease treatment updates — RSS
- Ménière's disease treatment updates — Atom
- Ménière's disease treatment updates — JSON
Cite this brief
Drug Landscape (2026). Ménière's disease — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/m-ni-re-s-disease. Accessed 2026-06-10.
Related
- Ménière's disease full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing